Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Bioretec Ltd Company announcement 28 August 2025 at 10:15 a.m. EET

 

Bioretec Ltd has on 28 August 2025 received a notification in accordance with the Securities Market Act, according to which the holdings of shares and votes of W&M GmbH in Bioretec Ltd have on 25 August 2025 crossed below the threshold of 5%.

 

Total position of W&M GmbH according to the notification:

 

	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both in %	Total number of shares and voting rights of the issuer
Resulting situation on the date on which threshold was crossed or reached	4.47%	0%	4.47%	30,783,092
Position of previous notification (if applicable)

 

Notified details of the resulting situation on the date on which the threshold was crossed:

 

	Number of shares and voting rights		% of shares and voting rights
Class/type of shares ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000480454	1,377,503	0	4.47%	0%
SUBTOTAL	1,377,503		4.47%

 

After 28 August 2025, W&M GmbH holds 4.47% of the shares and votes.

 

 

Further enquiries

Johanna Salko, CFO, +358 40 754 8172

 

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

 

About Bioretec  

 

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.  

 

Bioretec’s Activa® product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA polymer. These implants deliver secure fixation through patented innovations and naturally degrade in approximately two years, eliminating the need for costly removal surgeries while supporting optimal bone regeneration. Activa products are both CE marked, and FDA cleared for a wide range of indications in adult and pediatric patients.

 

The company’s latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. With the development of next-generation implants like RemeOs, Bioretec is shaping the future of orthopedic treatment, paving the way for more effective and patient-friendly solutions.

 

To learn more about Bioretec, visit https://bioretec.com.

 

 

 

---